more nieb, meg tyrell enchts best buyiring on all cylinders heading into the holiday season.he big box retail are reported better than expected earnings and raised guidance. that sent the stocks up more than 9% to a 52-week high. courtney reagan looks at what this brick and mortar big box retailer is doing right at a time when digital seems to dominate. >>> best buy is riding momentum into black friday. the consumer electronic's retail heed posted of a legislate 11th grade quarter of sales growth exceeding expect expectation. plus increasing the foerngt for the year improves outlining for the holiday season. last quarter best buy expected a broader consumer spending slowdown as a result of higher prices from tariffs. but the consumer has held on. economic data points remain positive. and most retail groups expect holiday sales growth. ceo cory barry said there is more certainty in the forecast and excited about the holiday zbloonz i think the best buy position, the tariff worry does not seem as severe. i think we're past that but really the key here is you have a very healthy

brian. >> meg tyrell, thank you very much. >> guys these are big names. the stocks hit today but this is an issue talking about a criminal probe not a civil the case talking about criminal charges here, guy. >> the headline risk is significant. mckesson for example -- it's done this a number of times in the last six month 130, 155, back to 130, back to 155 probably headed back down to the 135 level. you trade these don't own them because that's not the environment we find ourselves. people say mckesson is cheap s it but the headline too severe down 7% my sense there is further room down. but at a 135 level i think you close your eyes and buy it again. >> if you think it about it j&j those the movie diversified and biggest biggest balance sheet and rallied on the small state settlements in terms of civil charges. if you think about the headline fliing in the face of -- frankly on janzen johnson a handful of fronds you don't have to run in and buy it but you have a dynamic with a company that's made it clear there are places where they think where it's wort

let's get to meg tyrell back at cnbc headquarters with the story. >> high drug prices what the industry it's the opposite situation causing a simering problem for the health care system many life saving drugs older and cheaply priced in shortage we spoke with karen high on top of a diagnosis with bladder cancer was told the best drug for her wasn't available >> this thing works but it's very difficult for anybody to make money off of it but if we don't have enough of it people suffer and die >> the drug is called bcg. decades old and cheap for aens kaer drug. $157 a vile. also extremely complex to manufacture. and after santa fe had quality issues it dropped out of the market in 2016 no merck is the only supply are. who while it's doubled output the shortage persist we asked the ceo about it back in june. >> when the provides of drugs get too low, particularly drugs generic drugs then you don't have a market incentive for people toput the capital up to build facilities like we need more additional amounts of the bcg drug. >> so why not raise the price to support more manufacturing well

. >> we're welcoming back meg tyrell who spoke to us just a moment ago. >> i would love to ask a questionspoke with dr. scott gotlieb who said juul should come off the market completely. they have taken off the mint-flavored pod which was 70% of their sales all of this, even if there was a broad band, would potentially be until next may when it comes time for companies to approve for the license to get the products on the market do you think they can prove that there's a public health benefit to the public so they can continue selling these products? >> there's been a lot of rigorous r & d that's gone into understanding the companies of the vapor aerosol and the chemical constituents within it, and i think it's really up to the fda to help offer a framework what kind of science they are looking for specificfully and then for us on the investing side we need a bet per understanding of how the fda will really weigh the true health risks and/or benefits in terms of the chemical properties of the products and they want to protect youth from entering the vaping category. >> i was just going to